Chamazulene is the deep-blue azulene derivative most associated with German chamomile, blue tansy, and some yarrow or wormwood oils in the AromaForge archive. Live sources support its identity, its formation from matricine during steam distillation, and a meaningful but still preclinical research base around antioxidant and inflammation-related assays. The archive-safe framing is that chamazulene is a color-signature constituent with moderate laboratory evidence and limited isolated-compound human safety or efficacy data.
Chemical identity and composition
PubChem identifies chamazulene as C14H16 with the IUPAC name 7-ethyl-1,4-dimethylazulene. Cosmetic-safety literature for chamomile-derived ingredients notes that chamazulene is formed from matricine during steam distillation rather than being stored in that final form in fresh plant material. Recent degradation work also describes chamazulene as light-sensitive and oxidation-prone, which matters for blue-oil stability more than for therapeutic interpretation.
Aroma and practical use
- Use the recorded herbal, sweet, woody, balsamic, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1994 Planta Medica study found that chamazulene inhibited leukotriene B4 formation in intact cells and cell-free fractions, with reported IC50 values of 15 and 10 microM, while also blocking arachidonic-acid peroxidation at an IC50 of 2 microM.
This is one of the clearer isolated-compound mechanistic studies for chamazulene and supports a preclinical anti-inflammatory interpretation centered on leukotriene synthesis and antioxidative effects.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 antioxidant study reported higher total antioxidant activity for isolated chamazulene than for ascorbic acid, alpha-tocopherol, and BHT in the tested assay setup, and stronger ABTS radical scavenging despite no DPPH reactivity.
The paper supports chamazulene as one contributor to chamomile oil antioxidant behavior, but the endpoint is assay-based rather than clinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2020 open-access rat study reported that oral chamazulene at 25 and 50 mg/kg reduced liver-injury enzymes, malondialdehyde, TNF-alpha, and IL-6 while restoring glutathione, catalase, glutathione peroxidase, and SOD in an ethanol-injury model.
These data extend chamazulene research beyond test-tube assays, but they are still animal-model evidence and should not be read as human liver-use proof.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
Chamomile cosmetic-safety assessments describe chamazulene as a distillation-formed constituent and note lower membrane passage than most other tested chamomile-oil components in one transfer model, but they do not establish a standalone topical limit for isolated chamazulene.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Recent degradation literature states that chamazulene is unstable and degrades with light and oxidation, so color loss or chemistry drift is a formulation and storage issue for blue oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
alpha-BisabololAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
review · effect
No source citation attached.
Read alpha-Bisabolol report →beta-ElemeneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · antioxidant
No source citation attached.
Read beta-Elemene report →(E)-beta-FarneseneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · antioxidant
No source citation attached.
Read (E)-beta-Farnesene report →How the effects were investigated
leukotriene_b4_pathway_downshift
A 1994 paper reported concentration-dependent inhibition of leukotriene B4 formation in neutrophilic granulocyte systems, supporting a lipoxygenase-linked anti-inflammatory mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
oxidative_stress_signal_reduction
Rat-model and antioxidant-assay papers both support an oxidative-stress-related mechanism, with lower lipid peroxidation markers and improved antioxidant-enzyme readouts in preclinical settings.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated-compound human clinical trials for chamazulene were verified in this pass.
- A constituent-specific IFRA-style dermal limit or RIFM monograph for isolated chamazulene was not located in the reviewed public sources.
- Several public claims around chamazulene still rely on parent-oil reputation or cosmetic marketing language rather than direct human evidence.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.